ACT has already been used to inform the psychotherapy portions of psilocybin-assisted therapy in several clinical trials. Dr. Jordan Sloshower shares about his experiences working on a clinical trial of psilocybin-assisted therapy for depression. He discusses why his team chose ACT from among several potential therapy models, as well as his views on ACT’s strengths and weaknesses in preparation, dosing, and integration sessions involved in psilocybin-assisted therapy. We discuss how the development of psychedelic-assisted therapy challenges current paradigms in mental health treatment and may lead us to a more holistic model of understanding and treating mental health problems.